Ravel J, Brotman RM, Gajer P, Ma B, Nandy M, Fadrosh DW, et al. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. Microbiome. 2013;1(1):29.
Sobel J. Bacterial vaginosis. In: Barbieri R, Vanessa A, editors. Up To Date. Waltham; 2012. Accessed 1 Sept 2015.
Marrazzo JM. Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe. 2011;17(4):186–90.
Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med. 2008;149(1):20–8.
Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv. 2010;65(7):462–73.
Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59(RR-12):1–110.
Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996;51(4):621–38.
Videau D, Niel G, Siboulet A, Catalan F. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis 1978;54(2):77–80.
Hillier SL, Morgan FG, Waldbaum AS, Schwebke JR, Nyirjesy P, Adetoro N, Braun C. A phase 2 randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of single, oral doses of SYM-1219, a granule formulation containing 1 and 2 gram doses of secnidazole, for the treatment of women with bacterial Vaginosis data presented at the 42nd Annual Meeting of the Infectious Disease Society of Obstetrics and Gynecology (IDSOG), Portland OR, August 6–8.
Pentikis H, Adetoro N, Braun C. A Phase I study to determine the single dose, safety, and pharmacokinetics of SYM-1219 (secnidazole) in healthy female volunteers. Abstract presented at ASCPT 2015 Annual Meeting, March 3–7 2015, New Orleans, LA; 2015.
Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis. 2004;31(8):488–91.
Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J (Clin Res Ed). 1987;295(6602):814–8.
Back DJ, Houlgrave R, Tjia JF, Ward S, Orme ML. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol. 1991;38(2):219–25.
Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988;33(5):500–8.
Combined Nelson A, Contraceptives Oral. Contraceptive technology. 19th ed. New York: Ardent Media Inc; 2007. p. 193–270.
Lohr PA, Creinin MD. Oral contraceptives and breakthrough bleeding: what patients need to know. J Fam Pract. 2006;55(10):872–80.
Ortho-Novum [prescribing information]. Titusville: Janssen Pharmaceuticals, Inc.; 2009.
Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15(4):974–90.
Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15(6):657–80.
US Food and Drug Administration, (CDER). Guidance for industry: drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. Clin Pharmacol. 2012;1–79.
Chatterton JR. Pharmacology of contraceptive steroids. Glob Libr Women’s Med. 2012. doi:10.3843/GLOWM.10386.
Kuhnz W. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. Am J Obstet Gynecol. 1990;163(6 Pt 2):2120–7.
Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet. 1983;8(2):95–136.